Godawari Power & Ispat conducted their conference call today at 12 noon
"Co. is targeting to be debt free company soon"
Here are the key takeaways π
Business Updates:
β’ In- plant power generation capacity of 73 MW
β’ Thermal Power is yielding 12%, hence co. is expanding in Solar Pvr
β’ Utilization level- 92-95%
β’ Iron Ore availability is expected to consistent from this year
β’ MOU signed with Chattigarh for future project
Solar PV Power:
β’ Setting up a 250 MW captive Solar PV power plant to replace existing thermal capacity.
β’ Project will commissioned in Q3 Fy 2023.
β’ Project Dynamics of project mentioned in image
β’ Expected returns is 24%, hence now Godawari is investing heavily.
Mining Benefit:
β’ Last year Godawari has purchased 20% of requirement at 5,000 per tonne.
β’ This year co. is first planning to consume the inventory.
β’ Co. has increased captive mining for lowering cost. Once co. receive the approval, capacity would be increased.
Pellet:
β’ MOU with chattisgarh withe expansion of green field.
β’ Most of captive power would be green power only.
β’ Will expanding the facility once the company feels need.
β’ Current realization is around 15K.
β’ Capacity Utilization mentioned in image.
Raw Material:
β’ Godawari would be sourcing import : domestic at ratio of 75:25
Acquisition:
β’ Acquisition was cancelled and the Godawari has used that to pay the debt.
Forex:
β’ All export and import co. is hedged partially and no much big threat.
Geographic market:
β’ Godawari market in China is going good. There were price rise, which now cooled down.
β’ Major sales in China, Malaysia, Indonesia
Finish side- Philipines, Africa, Indonesia
β’ Logistics concern as of now is not there.
β’ Co. has order book till mid of July.
Price Realization:
β’ China has targeted speculation in futures market of commodity, and price is cooled as of now
β’ China has withdrawn 13% tax benefit from export, to reduce export sales.
β’ China has been importing steel heavily.
β’ Price of steel has only come down in china.
β’ Steel exports of China is difficult to supply by other countries, as India too don't have such capacity.
β’ Mgmt don't expect much scope of more higher prices in commodity, however there wont be even dip of more than 5%.
Competitive:
β’ Tata Steel is in small producct, while Godawari is in long product, and the realization is around 15K.
β’ Godawari has maximize the sales of high grade pallet.
Loan:
β’ Rate of Interest in 8%.
Group Structure:
β’ Merger of Jagdamba and GPIL is delayed.
β’ Stake has been reduced from 76% to 38%.
For more discussion on Equity research and OI analysis
IG Petrochemicals Ltd. Conducted their conference call today at 3:30 pm.
" To become a well diversified chemical company with leadership in PAN* Industry. "
Here are the key takeaways π...
Business Overview
- Company has given robust growth in both QoQ and YoY basis.
- They still maintain their position of being the largest manufacturer of phthalic Anhydride (PAN) and maleic anhydride.(MAN)
- With government demand being bullish on downstream products like Paints, Plasticizers, UPR and all , there will be demand of PAN in domestic markets.
- They have a positive correlation with the infrastructure industry leading to a strong demand growth.
Balaji Amines conducted their Conference Call today at 4:00 pm.
Here are the key takeaways π
Business Updates:
β’ EBIDTA growth- 78% Driver were increasing demand and improving price realization.
β’ Zero debt co. on standalone basis.
β’ Certain product are now exported to China.
Ethylamines:
β’ With implementation of new technology the cost of production is expected to lower.
β’ Demand is India is expected to increase by 12-15% over years.
β’ Import of Ethylamines is 9,000 Tones in India.
β’ Majority will be sell directly in market.
Indoco Remedies Ltd. Conducted their conference call today at 3:30 pm.
" Company motivated to earn 19% above CAGR"
Here are the key takeaways π
Business Overview
- Company have nominal profit on YoY basis and has experienced a decline in growth on QoQ basis.
- Company still remains bullish on their key segments for further growth.
- The major impacted acute segment witness strong hit due to fall in demand.
- The Company experience about 20% de growth in the prescription buisness. And as the covid situation is falling apart they will be able to cover up the losses.
- Their Domestic business has taken the major hit this quarter but was covered somewhat by international growth.
Alkem Laboratories conducted their conference call today at 4:30.
"Guidance for EBIDTA margins to be around 20%"
Here are the key takeaways π
Business Update:
β’ India business grew 17.1% YoY.
β’ Therapy segment grew well, of which major contribution of growth is Anti-Diabetic, Neuro, Vitamins, Gastro.
β’ In this quarter Alkem has filed 4 new ANDA and received 10 approvals.
FY21- 9 ANDA filed with 25 approval.
Gross Margin:
β’ Inventory Provision of 80 cr was taken, which declined margins.
β’ In More than 6 months inventory, if NRV seems to be unrecognizable, provision is made.